| Description | BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM). |
| In vitro | In WT cells, BMS 753 can reduce RAR β Transcription level of 2 in a dose dependent mode. At RAR γ-/- cells, 100 nM of BMS 753 efficiently induces RAR β 2 Transcription. In contrast, in RAR α-/- In cells, up to 100 nM of BMS 753 can not activate RAR β 2[1]. |
| Target activity | RARα:2 nM (Ki) |
| molecular weight | 351.4 |
| Molecular formula | C21H21NO4 |
| CAS | 215307-86-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45.0 mg/mL (128.1 mM), Sonication is recommended. |
| References | 1. M Géhin, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999 Aug;6(8):519-29. 2. R Taneja, et al. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR beta 2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc Natl Acad Sci U S A. 1996 Jun 11; 93(12): 6 |